摘要
目的评价布地奈德福莫特罗粉吸入剂治疗稳定期慢性阻塞性肺病(COPD)患者的临床效果。方法依据纳入排除标准选取80例稳定期COPD患者,并随机分为两组,其中对照组采用噻托溴铵治疗,研究组在此基础上加用布地奈德和福莫特罗粉;比较两组患者的血气分析、肺功能指标以及临床疗效。结果研究组患者治疗后血气分析、肺功能指标均较对照组有明显改善;差异均有统计学意义(P﹤0.05);研究组治疗后的总有效率为90.00%,高于对照组(62.50%),差异有统计学意义(P﹤0.05)。结论布地奈德加福莫特罗粉吸入剂治疗治疗稳定期COPD患者的临床效果较佳,可有效改善病人的肺功能,避免症状加重,值得临床上推广使用。
OBJECTIVE To evaluate budesonide and formoterol inhalant for the treatment of stable chronic obstructive pulmonary dis-ease(COPD) patients with clinical effect. METHODS According to the inclusion and exclusion criteria,80 patients with stable COPD patients were selected and randomly divided into two groups, the control group was treated with tiotropium bromide in the treatment of, study group based on the use of budesonide/formoterol fumarate powder; compared two groups of patients with blood gas analysis,pulmonary function and clinical curative effect. RESULTS the blood gas analysis and pulmonary function index of the study group were significantly improved compared with the control group(P<0.05); the total effective rate of the study group was 90%, higher than the control group(62.50%), the difference was statistically significant(P<0.05). CONCLUSION Budesonide and formoterol fumarate powder for inhalation therapy in the treatment of COPD patients in the stable phase had clinical effect better, effectively improve the patient's pulmonary function and avoid symptoms,which was worthy of clinical use.
出处
《中国初级卫生保健》
2016年第1期82-83,共2页
Chinese Primary Health Care
